Hatch Eyes FDA For Move On Generic Biologics

Law360, New York (October 13, 2005, 12:00 AM EDT) -- Utah Senator Orrin Hatch is waiting to see how a closely watched lawsuit against the U.S. Food and Drug Administration plays out before taking any steps toward proposing legislation for generic biotech drugs, his office said Thursday.

The influential chairman of the Senate’s newly minted Intellectual Property Subcommittee, who co-wrote the groundbreaking law that created the market for generic drugs in the U.S. in the 1980s, told IP Law Bulletin he planned to review the outcome of generic drug maker Sandoz’s lawsuit against the FDA before...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.